NME
VRTX icon

Notis-McConarty Edward’s Vertex Pharmaceuticals VRTX Stock Holding History

Notis-McConarty Edward’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.18M Buy
8,423
+538
+7% +$238K 1.81% 21
2026
Q1 		$3.52M Buy
7,885
+31
+0.4% +$14.5K 1.75% 23
2025
Q4 		$3.56M Buy
7,854
+50
+0.6% +$21.6K 1.65% 22
2025
Q3 		$3.06M Buy
7,804
+423
+6% +$177K 1.42% 27
2025
Q2 		$3.29M Buy
7,381
+106
+1% +$48.8K 1.6% 24
2025
Q1 		$3.53M Buy
7,275
+756
+12% +$352K 1.81% 23
2024
Q4 		$2.63M Buy
6,519
+1,257
+24% +$583K 1.27% 27
2024
Q3 		$2.45M Buy
5,262
+1,475
+39% +$709K 1.11% 30
2024
Q2 		$1.78M Buy
3,787
+2,462
+186% +$1.07M 0.7% 39
2024
Q1 		$554K Buy
+1,325
New +$560K 0.22% 65

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Notis-McConarty Edward's VRTX Position: Q2 2026 in Review

Notis-McConarty Edward increased its Vertex Pharmaceuticals (VRTX) stake by 6.8% in Q2 2026, buying an estimated $238K and bringing the position to 8,423 shares worth $4.18M. The position accounts for 1.81% of the portfolio, ranked #21.

Notis-McConarty Edward first reported a position in VRTX in Q1 2024 and has held it in 10 quarters since. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Notis-McConarty Edward held 8,423 shares of Vertex Pharmaceuticals worth $4.18M as of Q2 2026.
  • Notis-McConarty Edward bought 538 Vertex Pharmaceuticals shares in Q2 2026, an estimated $238K.
  • Vertex Pharmaceuticals made up 1.81% of Notis-McConarty Edward's portfolio in Q2 2026, its #21 holding.
  • Notis-McConarty Edward first reported a position in Vertex Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
  • 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Notis-McConarty Edward's 13F filing for Q2 2026, filed 11 Aug 2026.